Core Viewpoint - The company Guangdong Zhongsheng Pharmaceutical Co., Ltd. announced that its innovative drug, Angladiwei Tablets (brand name: Anruiwei), has been included in the National Medical Insurance Directory for 2025, which is expected to enhance market promotion and sales potential for the product [1][2]. Group 1: Product Information - Angladiwei Tablets are the world's first targeted drug for the PB2 subunit of the influenza A virus RNA polymerase, approved for treating adult patients with uncomplicated influenza [2]. - The drug is characterized by rapid action, strong efficacy, and low resistance, providing a cost-effective and accessible treatment option for patients [2]. Group 2: Market Impact - The inclusion of Angladiwei Tablets in the National Medical Insurance Directory is anticipated to positively impact the company's long-term operational development and market presence [2]. - Other core products of the company, including Lai Ru Te Wei Tablets and various other formulations, continue to be listed in the National Medical Insurance Directory, supporting the company's overall product portfolio [1].

Core Viewpoint - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has successfully included its innovative drug, Anladiwei Tablets (brand name: Anruiwei), in the National Medical Insurance Directory for 2025, which is expected to enhance patient access to effective treatment for influenza [1] Group 1: Product Inclusion - Anladiwei Tablets is the first global drug targeting the PB2 subunit of the RNA polymerase of the influenza A virus, approved for the treatment of uncomplicated influenza in adults [1] - The drug is characterized by rapid action, strong efficacy, and low resistance, providing a significant option for patients suffering from influenza [1] - Other core products of the company, including Lai Ru Te Wei Tablets and various formulations, continue to be included in the National Medical Insurance Directory [1] Group 2: Market Impact - The inclusion of Anladiwei Tablets in the Class B category of the National Medical Insurance Directory is expected to benefit a larger patient population, offering economical, safe, and accessible medication options [1] - The drug was approved by the National Medical Products Administration in May 2025, marking a significant milestone for the company's respiratory pipeline [1]

Core Viewpoint - Zhongsheng Pharmaceutical's innovative drug, Angladiwei Tablets (brand name: Anruiwei), has been included in the National Medical Insurance Directory for the first time through national medical insurance negotiations [1] Group 1: Company Developments - The company announced that its core product, Lai Ru Te Wei Tablets, along with several other products, continues to be included in the National Medical Insurance Directory [1]

Core Viewpoint - Zhongsheng Pharmaceutical's innovative drug Angladewe Tablets (brand name: Anruiwei) has been included in the National Medical Insurance Directory for the first time through national medical insurance negotiations for 2025 [1] Group 1: Company Developments - The company announced that its core products, including Lai Ru Te Wei Tablets, Compound Thrombus Tong Capsules, Cerebral Thrombus Tong Capsules, Sucralfate Oral Suspension, Carboxymethyl Starch Oral Solution, and Nitazoxanide Eye Drops, have also been included in the National Medical Insurance Directory [1]